Protagonist Therapeutics
PTGX
PTGX
128 hedge funds and large institutions have $875M invested in Protagonist Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 48 increasing their positions, 21 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
20% more capital invested
Capital invested by funds: $728M → $875M (+$147M)
12.12% more ownership
Funds ownership: 101.29% → 113.41% (+12%)
76% less call options, than puts
Call options by funds: $214K | Put options by funds: $901K
Holders
128
Holding in Top 10
3
Calls
$214K
Puts
$901K
Top Buyers
| 1 | +$38.3M | |
| 2 | +$25.2M | |
| 3 | +$11.1M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.38M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$7.26M |
Top Sellers
| 1 | -$27.6M | |
| 2 | -$6.99M | |
| 3 | -$6.55M | |
| 4 |
Renaissance Technologies
New York
|
-$6.07M |
| 5 |
D.E. Shaw & Co
New York
|
-$3.85M |